ADDED
Silexion Therapeutics Corp - 2022416 - 2026 Represents an amount less than $1 Net of 28 treasury shares held by the Company as of December 31, 2024 false 0002022416 FY 00-0000000 Other segment expenses include mainly general and administrative-related expenses, such as rent and maintenance expenses, travel and HR expenses.
As of March 10, 2026, 3,330,785 ordinary shares, par value $0.0135 per share, were issued and outstanding.
Our approach targets a significant unmet medical need, as treatment innovation for KRAS-driven cancers has historically lagged despite KRAS being one of the most common oncogenic drivers across solid tumors.
Our lead product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy, and uses an integrated treatment approach that combines intratumoral and systemic administration.
We were formed through a business combination that was completed on August 15, 2024, when Silexion Therapeutics Corp (then known as Biomotion Sciences) consummated previously-announced transactions with Silexion Therapeutics Ltd.
Following the business combination, we changed our name to Silexion Therapeutics Corp and our ordinary shares and warrants commenced trading on the Nasdaq Global Market (and were subsequently transferred to the Nasdaq Capital Market, where they currently trade) under the symbols SLXN and SLXNW , respectively.
Unless otherwise indicated or the context otherwise requires, all references in this annual report (this Annual Report ) to we , us , our , the company , the Company , our company or Silexion are to Silexion Therapeutics Corp, a Cayman Islands exempted company, which is filing this Annual Report, and, with respect to periods following the Business Combination, include the Company and all of its subsidiaries (including Silexion Therapeutics Ltd.
Wainwright pursuant to the ATM Agreement; "ATM Agreement" are to the At The Market Offering Agreement, dated September 26, 2025, to which we are party with H.C.
Securities Act of 1933, as amended; Silexion Israel are to Silexion Therapeutics Ltd., an Israeli company and our wholly-owned subsidiary through which our operations are primarily conducted; warrants are to our warrants to purchase ordinary shares, consisting of (i) public warrants and private warrants issued pursuant to the Business Combination in exchange for corresponding warrants of Moringa, as well as (ii) warrants that we have issued and sold in public offering(s) and/or private placements subsequent to the Closing of the Business Combination; and $, US$ and U.S.
iv We will need to raise substantial additional funding, which may not be available on acceptable terms, or at all, and which will cause dilution to our shareholders and may cause a decrease to the trading price of our ordinary shares.
REMOVED
** Represents exercises of fully vested pre-funded options for the Company s ordinary shares at an exercise price of $0.0226 or 0.0226 NIS per share **** Net of 421 treasury shares held by the Company as of December 31, 2024 Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.
As of March 1, 2025, 8,414,615 ordinary shares, par value $0.0009 per share, were issued and outstanding.
Our lead product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy.
On August 15, 2024, Silexion Therapeutics Corp (then known as Biomotion Sciences), a Cayman Islands exempted company ( New Silexion ), consummated the previously announced transactions pursuant to that certain Amended and Restated Business Combination Agreement, dated as of April 3, 2024 (as amended, the Business Combination Agreement ), by and among New Silexion, Moringa Acquisition Corp ( Moringa ), August M.S.
Ltd., an Israeli company and a wholly-owned subsidiary of New Silexion ( Merger Sub 1 ), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and a wholly-owned subsidiary of New Silexion ( Merger Sub 2 ), and Silexion Therapeutics Ltd., an Israeli company ( Silexion ).
The transactions contemplated by the Business Combination Agreement are hereinafter referred to as the Business Combination .
In connection with the consummation of the Business Combination (the Closing ), New Silexion changed its name from Biomotion Sciences to Silexion Therapeutics Corp .
Unless otherwise indicated or the context otherwise requires, all references in this annual report (this Annual Report ) to we , us , our , the company , the Company , our company or New Silexion are to Silexion Therapeutics Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company, which is filing this Annual Report, and, with respect to periods following the Business Combination, include the Company and all of its subsidiaries (including Moringa and Silexion), on a consolidated basis.
We will need to raise substantial additional funding, which may not be available on acceptable terms, or at all, and which will cause dilution to our shareholders.
Our recent reverse share split may negatively impact the market for our ordinary shares.